Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product -- Ignore unavailable to you. Want to Upgrade?

To: geewiz who wrote (434)	1/13/2000 1:06:00 PM
From: geewiz	Read Replies (1) \| Respond to of 534

CEGE Recent Patent; Thursday January 6, 7:30 am Eastern Time <<Company Press Release SOURCE: Cell Genesys, Inc. Cell Genesys Issued Second Patent for Lentiviral Gene Therapy Technology High Efficiency Vectors Target Genetic Deficiency Disease FOSTER CITY, Calif., Jan. 6 /PRNewswire/ -- Cell Genesys, Inc. (Nasdaq: CEGE - news) today announced that the company has been issued a second patent (U.S. Patent No. 5,994,136) from the United States Patent Office covering the company's third-generation lentiviral gene delivery system. The issued patent includes composition of matter claims covering the company's lentiviral vector system including novel safety features to prevent the gene therapy vector from giving rise to disease-causing virus during patient treatment. ``Lentiviral-based vectors can produce high levels of prolonged gene expression in both non-dividing and dividing cells thereby creating the potential to treat a wide range of genetic diseases. The combination of the levels and duration of gene delivery seen with viral vectors such as these, significantly exceeds that seen with non-viral gene delivery systems,' stated Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys. ``As a result, we are now actively pursuing preclinical studies with lentiviral vectors targeting genetic deficiency diseases including hemophilia.' In late 1998, Cell Genesys received U.S. Patent No. 5,834,256, which has broad claims for methods of producing retroviral vectors including lentiviral vectors. Such vector systems have applicability for both human gene therapy and gene-based drug discovery as a target validation technology. The company's patent portfolio includes issued or granted patents for multiple gene delivery systems in addition to those that are lentiviral-based. Cell Genesys currently has one of the largest patent portfolios in the gene therapy field including approximately 220 issued or granted patents and 335 patent applications pending.>> It's interesting to me that of over 300 gene-therapy trials only a handful have yielded a response the FDA deemed significant... could it be the delivery? later art